Capital Market Strategies LLC Increases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Market Strategies LLC increased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 82.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 21,367 shares of the company's stock after purchasing an additional 9,652 shares during the period. Capital Market Strategies LLC's holdings in CRISPR Therapeutics were worth $727,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Wood Tarver Financial Group LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth approximately $30,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter worth approximately $36,000. Western Pacific Wealth Management LP increased its position in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares during the period. GF Fund Management CO. LTD. acquired a new position in CRISPR Therapeutics during the 4th quarter worth approximately $71,000. Finally, Spire Wealth Management increased its position in CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

CRSP stock traded up $0.94 during midday trading on Tuesday, reaching $37.89. The company had a trading volume of 922,323 shares, compared to its average volume of 1,709,340. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88. The company has a market capitalization of $3.27 billion, a P/E ratio of -8.67 and a beta of 1.88. The firm has a 50-day moving average price of $36.54 and a 200-day moving average price of $41.32.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the previous year, the firm posted ($1.43) earnings per share. The business's revenue was up 71.6% compared to the same quarter last year. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In related news, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 9,973 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares of the company's stock, valued at $7,673,353.80. This trade represents a 5.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,953 shares of company stock valued at $736,087. Corporate insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of research reports. Barclays lowered their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Citigroup cut their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, February 18th. The Goldman Sachs Group lowered their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.